Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring

Pharmacology, Toxicology and Pharmaceutical Science

• Repurposing 100%
• Drug Administration 50%
• Drug Information 50%
• Drug Formulation 50%
• Antimalarial Agent 50%
• Adverse Event 50%
• Antivirus Agent 50%
• Immunoglobulin 50%
• Remdesivir 50%
• Hydroxychloroquine 50%
• Chloroquine 50%
• Lopinavir Plus Ritonavir 50%
• Drug Interaction 50%
• Middle East Respiratory Syndrome 50%
• Ciclesonide 50%
• Tocilizumab 50%
• Niclosamide 50%